Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 2/20 | 0.47 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | TP53 | P04637 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 6/20 | 0.38 |
| ▸ | RAB9A | P51151 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL17941330 | 0.98 | IMPDH2 (0.46) | IMPDH2IMPDH1ACHEALDH1A1TP53 | |
| SCHEMBL15929467 | 0.83 | IMPDH2 (0.50) | IMPDH2IMPDH1ACHEALDH1A1TDP1 | |
| SCHEMBL472455 | 0.80 | MAPK14 (0.54) | IMPDH2IMPDH1NPC1RAB9AMAPK14 | |
| SCHEMBL472411 | 0.80 | GAA (0.49) | IMPDH2IMPDH1ALDH1A1NPC1RAB9A | |
| SCHEMBL3998459 | 0.80 | IMPDH2 (0.50) | IMPDH2IMPDH1ACHETP53NPC1 | |
| SCHEMBL472419 | 0.80 | IMPDH2 (0.47) | IMPDH2IMPDH1ALDH1A1NPC1RAB9A | |
| SCHEMBL7896452 | 0.79 | NOS3 (0.44) | IMPDH2IMPDH1ALDH1A1NPC1RAB9A | |
| SCHEMBL17947429 | 0.79 | HRH3 (0.45) | IMPDH2IMPDH1ALDH1A1TP53NPC1 | |
| SCHEMBL343219 | 0.79 | ADORA2A (0.50) | IMPDH2IMPDH1ALDH1A1NPC1RAB9A | |
| SCHEMBL3441822 | 0.78 | MAP4K4 (0.47) | IMPDH2ALDH1A1NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11377425-B1 | Small molecule modulators of IL-17 | LEO PHARMA A/S (DK) | 2022-07-05 | — | — | US | disclosed |
| WO-2020127685-A1 | AMINO-ACID ANILIDES AS SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA A/S (DK) | 2020-06-25 | — | — | WO | disclosed |
| EP-1126843-A4 | COMPOUNDS DERIVED FROM AN AMINE NUCLEUS THAT ARE INHIBITORS OF IMPDH ENZYME | BRISTOL MYERS SQUIBB CO (US) | 2005-06-15 | — | — | EP | disclosed |
| US-6399773-B1 | AUTOIMMUNE DISEASE; TRANSPLANTING ORGANS | BRISTOL-MYERS SQUIBB CO. | 2002-06-04 | — | — | US | disclosed |
| EP-1126843-A1 | COMPOUNDS DERIVED FROM AN AMINE NUCLEUS THAT ARE INHIBITORS OF IMPDH ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-08-29 | — | — | EP | disclosed |
| WO-2000025780-A1 | COMPOUNDS DERIVED FROM AN AMINE NUCLEUS THAT ARE INHIBITORS OF IMPDH ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11377425-B1 | Small molecule modulators of IL-17 | IL17A, IL15, IL2 | IMPDH2 3518/4885IMPDH1 3455/4885ACHE 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.